Hector Granados
Pediatric Endocrinology · El Paso, TXNPI 1154616068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,875 of the $73,335 with a category attached, or 89.8%. Insulet Corporation accounts for 88.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $31,204 and has fallen 96.4% since, to $1,124 in 2025. Among pediatric endocrinology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $192.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$65K
- AbbVie$4K
- Dexcom, Inc.$816
- Novo Nordisk$651
- Abbott$618
- Ascendis Pharma Endocrinology Inc$597
- plus $2K from 22 others
Across 97 payments — averaging $2158.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$153K
- Antares Pharma, Inc.$27K
- Rhythm Pharmaceuticals, Inc.$16K
- Sanofi US Services Inc.$13K
What the payments were for
- Speaking & faculty fees$65,87590%
- Food & beverage$7,30610%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 147 | $65,055 |
| AbbVie | 57 | $3,526 |
| Dexcom, Inc. | 25 | $816 |
| Novo Nordisk | 18 | $651 |
| Abbott | 30 | $618 |
| Ascendis Pharma Endocrinology Inc | 18 | $597 |
| Medtronic(2 entities) | 8 | $239 |
| Inspire Medical Systems, Inc. | 2 | $213 |
| Tolmar Pharmaceuticals, Inc. | 11 | $196 |
| Pfizer | 8 | $149 |
| Sanofi-aventis U.S. LLC | 4 | $147 |
| Xeris Pharmaceuticals, Inc. | 8 | $143 |
| BETA Bionics, Inc. | 1 | $134 |
| Rhythm Pharmaceuticals, Inc. | 5 | $107 |
| Soleno Therapeutics, Inc. | 4 | $104 |
| Arbor Pharmaceuticals, Inc. | 6 | $104 |
| Ultragenyx Pharmaceutical Inc. | 6 | $102 |
| AstraZeneca | 5 | $74 |
| Neurocrine Biosciences, Inc. | 2 | $71 |
| Tandem Diabetes Care, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $52 |
| Tolmar, Inc. | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 3 | $49 |
| Biomarin Pharmaceutical Inc. | 1 | $21 |
| GSK | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$63,734
- Lupron Depot$2,359
- iLet Bionic Pancreas$402
- DEXCOM G6 TRANSMITTER$376
- SKYTROFA$230
- Inspire$213
- Minimed 670G System$124
- DEXCOM G7 GSS (161)$122
- DEXCOM STELO GLUCOSE BIOSENSOR$122
- Sogroya$106
How this compares
$73,335 in reported general payments places this provider in the 95th percentile of 120 pediatric endocrinology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 14 | $64 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in El Paso
- Sanjeet SandhuEl Paso$5K
- Michele ZerahEl Paso$2K
- Jose Gamez-GodoyEdinburg$207K
- Virginia AraizaHouston$151K
- Daniel DesalvoHouston$133K
- Amy BurtonPlano$130K
- Susan NunezAustin$91K
- Donnie WilsonFort Worth$58K
- Paul ThorntonFort Worth$52K
- Jane LynchSan Antonio$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.